CD274 and non-small cell lung carcinoma: Taken together, the above phase 3 clinical trials provide evidence that toripalimab in combination with chemotherapy conferred better OS than chemotherapy alone in first-line treatment of patients with advanced and/or metastatic NPC, NSCLC or ESCC irrespective of PD-L1 expression.